Cologuard (EXAS): רווח נקי למניה (EPS TTM)

The complexity of maintaining sterile laboratories at Exact Sciences (EXAS) contrasts with the high efficiency of its automated biomaterial analysis systems. The current trailing twelve-month EPS helps balance these factors, with the parameter stabilizing at -1.09. Business stability is complemented by an environmental approach based on the safe disposal of reagents and energy-efficient facilities.

Net income per share (TTM) measures the company's total net income over the last twelve months, allocated per common share to evaluate the actual return on equity. By analyzing the trend of fundamental TTM earnings per share, an investor can see the impact of financial reports on the capitalization of Exact Sciences (EXAS) during a period of aggressive diagnostic platform implementation and the market expansion of new oncology tests.